Urology Times staff

“Any kind of complicated cancer surgery requires an experienced team from beginning to end,” says David Lee, MD.

“We had fantastic completion of the study, and we were very pleased with the results,” says Samantha Pulliam, MD.

"β3 agonists really provided a new drug class of medications for patients with overactive bladder. Previously, there were no alternatives," says Ekene Enemchukwu, MD, MPH.

“We talked about patient buy in but family caregiver buy in is just as important, especially when we're talking about cancer,” says Shirley Lee, CRNP-FNP.

“In urology, and really medicine as a whole, I think we're all really striving to build that championship-caliber team, and we're looking at recruiting diverse talent, but if we don't take the time to create the environments where all the team members can reach their full potential, then we as a whole may never reach our full potential in medicine,” says Ekene Enemchukwu, MD, MPH.

“This is a unique device in that it shows motion-based biofeedback,” says Samantha Pulliam, MD.

“We…just need to apply operational efficiencies that are utilized in other industries [to] health care,” says Shirley Lee, CRNP-FNP, MPH.

“Status quo EHR [and] status quo documenting [are] not going to give us the insights that we really need about how [patients are] doing now, and what are the opportunities we have to improve their care,” says Shirley Lee, CRNP-FNP, MPH.

“Clinically speaking, it really can harm patients to have gaps in both the data and their care,” says Shirley Lee, CRNP-FNP, MPH.

At standard stimulation parameters, the Axonics F15 system is expected to function for 15+ years; at lower energy settings, this extends to 20+ years.

"I would say our greatest advance of the past 30 years is our clinical trials infrastructure, because we can now use our therapies with intelligence," says Anthony Zietman, MD.

“Overall, there's no known advantage or disadvantage in a head-to-head trial of either one of these, but I do think they're complementary,” says Scott T. Tagawa, MD, when discussing radium-223 dichloride and lutetium Lu 177 vipivotide tetraxetan.

“If approved, tebipenem could provide a new oral treatment option for patients with cUTI who have limited or no alternative oral options," says Angela Talley, MD.

“I think we are good at treating the cancer but maybe not great at treating the patient as a whole. And that is an area that we can improve going forward based on research like this,” says Amy N. Luckenbaugh, MD.

In this conversation, Acacia Brush Perko, Esq, and Kenton H. Steele, Esq, discuss the qualities that comprise a good expert witness in a malpractice lawsuit.

“I think that the utilization of social media for professionals is only going to grow. And I would really encourage people at every level to start to dip their toe in the water and explore Twitter or other social media platforms,” says Casey Seideman, MD.

“We kind of expected that treatment type wouldn't make a ton of difference in terms of…mental health outcomes after either surgery or radiation…but we were very clearly able to find groups of people who were at risk for poor mental health outcomes,” says Amy N. Luckenbaugh, MD.

“Oral tebipenem pivoxil hydrobromide and intravenous ertapenem had a similar safety and tolerability profile,” says Angela Talley, MD.

"Now, men have the option to seek out something minimally invasive before surgical options are breached," says Denise Asafu-Adjei, MD, MPH.

"Peyronie's disease has really seen a wide range of intralesional options through the years," says Denise Asafu-Adjei, MD, MPH.

“I think the take home message is not to take sacral neuromodulation off the table,” says Sarah Martin, DO.

“The take-home message is that there is a new form of lithotripsy,” says Jonathan D. Harper, MD.

“The social needs aren't medical conditions that can be alleviated in a doctor's office, and they shouldn't be medicalized or viewed in that way,” says Elisabeth M. Sebesta, MD.

It was previously reported that UroLift received reimbursement approval from the Central Social Insurance Medical Council of Japan (Chuikyo).

“We are not just changing toxins for the sake of changing toxins; we are changing toxins to satisfy the needs from the clinical community,” says Min Dong, MD.

“Patients need to understand that even if you tell them that you may be doing this as an ambulatory procedure, they may actually have to stay afterwards, depending on what you find in the operating room or what happens in the postoperative period,” says Michael A. Palese, MD.

“We saw that this appears to be a safe treatment with very little bleeding,” says Jonathan D. Harper, MD.

“I think the take-home point here is that patient-centered care in the form of navigators to help support patients and provide those frequent check ins really appears to help improve adherence to therapy and progression to advanced therapies,” says Ekene Enemchukwu, MD, MPH.

"Throughout the years, I've said it's not hard to destroy tissue; it's hard to destroy tissue without destroying other things around [the cancer]," says J. Stephen Jones, MD, FACS.

"Cryotherapy was the first energy source that we were able to ablate tissues with in either the kidney or prostate and understand what that ablation would do," says J. Stephen Jones, MD, FACS.